Hope S. Rugo, MD, discussed KEYNOTE-B49 data showing pembrolizumab plus chemotherapy improved PFS in PD-L1-positive HR+/HER2- breast cancer.
|Articles|August 1, 1996
Oncology NEWS International
- Oncology NEWS International Vol 5 No 8
- Volume 5
- Issue 8
Kaiser Permanente to Evaluate Neopath's AutoPap 300 QC System
REDMOND, Wash--NeoPath Inc has signed an agreement with Kaiser Permanente to install AutoPap 300 QC Systems at its Northern California facility. Following a successful evaluation, Kaiser Permanente anticipates making the technology available to its nearly 2.5 million Northern California members.
Advertisement
REDMOND, Wash--NeoPath Inc has signed an agreement with KaiserPermanente to install AutoPap 300 QC Systems at its Northern Californiafacility. Following a successful evaluation, Kaiser Permanenteanticipates making the technology available to its nearly 2.5million Northern California members.
The AutoPap System rescreens Pap smear slides initially classifiedas normal, using high-speed image processing computers, videoimaging technology, and image interpretation software. In clinicaltrials in US laboratories, the system improved the detection rateof false-negative smears.
Articles in this issue
over 30 years ago
Chemo Improves Pain Relief in Advanced Prostate Cancerover 30 years ago
NCCR Urges Congress to Support Senate Bill for Cancer Researchover 30 years ago
Researchers Propose New Treatment Guidelines for HIVover 30 years ago
Salvage Cryotherapy for Prostate Cancer Studied at M.D. Andersonover 30 years ago
FNA Dropped From RDOG Study Due To High Rate of Insufficient Samplesover 30 years ago
New Thinking on HIV Progression Leads to New Strategiesover 30 years ago
Hospitals Told Not to Capitate for 'Wrong' Reasonsover 30 years ago
More Study Needed of Possible Carcinogenesis of Winter Gas Additiveover 30 years ago
President Makes NCAB AppointmentsAdvertisement
Related to this article
In a prospective cohort, a 3-gene blood model predicted 1-year castration resistance with an AUC of 0.89 in metastatic hormone-sensitive prostate cancer.
Rutika Mehta, MD, MPH, explains how she sequences MSI, HER2, claudin 18.2, and PD-L1 testing when tissue is limited in gastroesophageal cancer.
Dirk Schadendorf, MD, outlineed which patients with BRAF V600–mutant melanoma, including those with brain metastases, may be candidates for triplet therapy.
Dirk Schadendorf, MD, discussed final STARBOARD data with encorafenib, binimetinib, and pembrolizumab and its role in BRAF V600–mutant melanoma care.
Heath Skinner, MD, PhD, discussed the 3 considerations that determine which new radiation oncology service lines his network chooses to build.
Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.
Mingjia Li, MD, discussed the limitations of current biomarkers in selecting patients with resectable NSCLC for neoadjuvant chemoimmunotherapy.
Advertisement
Advertisement
Trending on CancerNetwork
1
Blood mRNA Model Predicts Castration Resistance in Metastatic Prostate Cancer
2
Prioritizing Biomarker Testing to Conserve Tissue in Gastroesophageal Cancer
3
Choosing Between Triplet Therapy and Immunotherapy in BRAF-Mutant Melanoma
4
Triplet Therapy Emerges as a First-Line Option in BRAF V600–Mutant Melanoma
5